Evidence map›Paper›PMID 41798119›Full record

ArticleNeuro-oncology practice2026

Tumor inflammation-associated neurotoxicity in children with diffuse intrinsic pontine glioma receiving B7-H3-targeting CAR T cells on BrainChild-03.

Rebecca Ronsley, Michelle Choe, Jason Wright, Kristy Seidel, Amy Lee, Jason Wendler, Colleen Annesley, Michael C Jensen, Julie R Park, Nicholas A Vitanza and 1 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04185038 (Phase 1 Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04185038 phase1recruitingnot on this map

Phase 1 Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

TypeinterventionalSponsorSeattle Children's HospitalRan2019 to 2042Enrolled90ConditionsCentral Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, EpendymomaArmsSCRI-CARB7H3(s), B7H3-specific chimeric antigen receptor (CAR) T cel
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rebecca RonsleyDepartment of Onclogy, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID https://orcid.org/0000-0003-3961-3042
Michelle ChoeDepartment of Onclogy, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Jason WrightPediatric Neuro-radiology, Department of Radiology, University of Washington, Seattle, WA, USA.
Kristy SeidelSeattle Children's Therapeutics, Seattle, Washington, USA.
Amy LeeDepartment of Neurosurgery, University of Washington, Seattle, Washington, USA.
Jason WendlerSeattle Children's Therapeutics, Seattle, Washington, USA.
Colleen AnnesleyDepartment of Onclogy, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Michael C JensenSeattle Children's Therapeutics, Seattle, Washington, USA.
Julie R ParkDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Nicholas A VitanzaDepartment of Onclogy, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID https://orcid.org/0000-0002-3966-4985
Juliane GustDivision of Pediatric Neurology, Department of Neurology, University of Washington, Seattle, Washington, USA.

Funding

B7-H3 CAR T cells following initial radiation for children and young adults with diffuse intrinsic pontine gliomaR37CA289981 · NCI · SEATTLE CHILDREN'S HOSPITAL · PI Nicholas A Vitanza · 2025 to 2026
$930k
NCI NIH HHS R37 CA289981
6 · The paper itself

Abstract

Background: Chimeric antigen receptor (CAR) T cell therapy is a promising treatment for central nervous system (CNS) tumors like diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG). Unlike systemic administration, locoregional CAR T therapy may result in tumor inflammation-associated neurotoxicity (TIAN), which was recently defined. This study retrospectively applies TIAN criteria to patients with DIPG/pontine DMG treated with intraventricular B7-H3 CAR T cells in the BrainChild-03 (BC-03) trial (NCT04185038). Methods: A retrospective analysis of DIPG/pontine DMG patients treated with locoregional B7-H3 CAR T cells in BC-03 was conducted. Neurological symptoms, headache, fever, hydrocephalus, and inflammatory markers were extracted from case reports and medical records. TIAN was classified as type 1 (mechanical damage) or type 2 (electrophysiologic dysfunction), and symptom patterns, resolution, imaging findings, and management were analyzed. Results: Among 21 patients (ages 2-22) receiving ≥1 infusion, 16 (76%) met TIAN criteria at least once. TIAN occurred in 49 of 152 infusions (32%), mostly grade 1 ( Conclusions: TIAN was common within this cohort but mostly low-grade and transient. Refining its classification and understanding its clinical impact will aid safety assessments and trial comparisons for CNS-directed CAR T therapies.

Indexed as

CAR-T therapyimmunotherapyneuro-toxicitypediatrictumor-inflammation associated neuro-toxicity

Identifiers

PMID41798119
PMCPMC12965641

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.